EXCLUSIVE: Clearmind Medicine's Psychedelic-Based Treatment Shows Encouraging Preclinical Activity In Obesity, Metabolic Disorders

Clearmind Medicine Inc CMND has released results from its pre-clinical trial of the combination therapy.

The treatment includes Clearmind's MEAI, a proprietary psychedelic treatment for various addictions, obesity and metabolic disorders, and depression, and SciSparc Ltd's SPRC Palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of its proprietary CannAmide.

The trial aimed to identify the optimal dosage for their combination to observe their safety and impact on various metabolic and behavioral parameters, including fat oxidation, locomotor activity, and feeding behavior.

Fourteen treatment groups were created (for 84 animals) receiving single doses ranging from 40, 20, 10, 5, 1 to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. 

MEAI administration exhibited a favorable degree of tolerance, leaving the animals' viability unaffected across all experimental groups. 

Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption, carbon dioxide emission, and elevated energy expenditure, and fat oxidation. Oxygen consumption and carbon dioxide emission indicate increased metabolic process and fat burn.

Food consumption (appetite) and meal sizes were also reduced, primarily at 40 and 20 mg/kg of MEAI. 

Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10 mg/kg.

Significant reductions in ambulation were noted at 40 and 20 mg/kg without affecting voluntary activity.

Clearmind Medicine recently announced a 1-for-30 reverse share split, effective today.